GLP-1 RECEPTOR AGONIST MARKET ANALYSIS

GLP-1 Receptor Agonist Market, By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Albiglutide, Semaglutide), By Route of Administration (Parenteral and Oral), By Application (Type 2 Diabetes Mellitus, Obesity, Liver Cirrhosis, Non-alcoholic Steatohepatitis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

On July 11, 2024, Pfizer Inc.global pharmaceutical company has announced the selection of its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, based on ongoing pharmacokinetic study results (NCT06153758). In the second half of 2024, Pfizer plans to initiate dose optimization studies to evaluate various doses of this formulation, aiming to inform registration enabling studies.
In February 2024, Eli Lilly and Company,American pharmaceutical company is poised to introduce Mounjaro, a successful medication for diabetes and obesity, into the Indian market next year pending regulatory approval. This move is expected to stimulate growth in the Indian market.
In January 2024, Novo Nordisk A/S,Pharmaceutical company unveiled research collaborations with two U.S. biotech companies as part of its strategy to lead in the development of new therapies for cardiometabolic disorders ahead of larger pharmaceutical firms.
In March 2023, the NHS approved Wegovy, a semaglutide injection for weight loss that mimics the hormone GLP-1 to suppress appetite. This approval will make Wegovy available to thousands of people with obesity in England.
In November 2021, Novo Nordisk A/S and Dicerna Pharmaceuticals, Inc. entered into a partnership to co-develop and commercialize RNA interference therapies targeting liver-related cardiometabolic diseases such as Non-Alcoholic Steatohepatitis (NASH) and type 2 diabetes.